乳腺癌COX-2和MMP-2的表达与新辅助化疗的关系  

Expression of COX-2 and MMP-2 in breast cancer and its relation to neoadjuvant chemotherapy

作　　者：蔡凤林[1] 周士福[1] 马兆生[1] 时伟锋[1] 吴玉玉[2] 高玮红[2] 

机构地区：[1]苏州大学附属第四医院肿瘤外科,江苏无锡214062 [2]苏州大学附属第四医院病理科,江苏无锡214062

出　　处：《中国肿瘤临床与康复》2008年第4期325-327,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的研究COX-2、MMP-2在乳腺癌新辅助化疗前后的表达变化,及其与新辅助化疗疗效的关系。方法应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、MMP-2的表达。结果新辅助化疗有效率为70.8%。化疗前后COX-2表达变化显著,由化疗前的62.5%降到化疗后的41.7%,(P<0.05);MMP-2表达无明显变化。化疗前后COX-2表达与MMP-2正相关,(P<0.05)。新辅助化疗前COX-2表达阳性者,化疗效果差(P<0.05),MMP-2表达与化疗疗效无关,(P>0.05)。结论COX-2可作为指导乳腺癌化疗并预测化疗敏感性的分子生物学指标,而MMP-2尚不能预测化疗疗效。Objective To observe the change of COX-2 and MMP-2 expression after neoadjuvant chemotherapy（NACT） in breast cancer and its correlation with the clinical response to NACT. Method COX-2 and MMP-2 were examined by immunohistochemical staining in 48 breast cancer samples. Results The overall response rate to neoadjuvant chemotherapy was 70. 8%. The expression of COX-2 after neoadjuvant chemotherapy was 41.7%, which was significantly lower than 62. 5% before neoadjuvant chemotherapy,P 〈0. 05. MMP-2 expression had no significant change. COX-2 had positive correlation with MMP-2 before and after NACT. The efficacy of NACT had a significantly negative correlation with COX-2 expression, but had no correlation with MMP-2. Conclusions The expression of COX-2 as a molecular marker could guide chemotherapy and predict the response to it in breast cancer,but MMP-2 could not predict the response to chemotherapy.

关 键 词：乳腺肿瘤/化学疗法 新辅助化疗 COX-2 MMP-2 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]